Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Abstract Text:

Whilst randomised control trials are undoubtedly the best way to demonstrate whether plasma exchange or infusion alone is the best first-line treatment for patients with atypical haemolytic uremic syndrome (aHUS), individual case reports can provide valuable information. To that effect, we have had the unique opportunity to follow over a 10-year period three sisters with aHUS associated with a factor H mutation (CFH). Two of the sisters are monozygotic twins. A similar natural evolution and response to treatment would be expected for the three patients, as they all presented with the same at-risk polymorphisms for CFH and CD46 and no identifiable mutation in either CD46 or CFI. Our report of different modalities of treatment of the initial episode and of three transplantations and relapses in the transplant in two of them, strongly suggest that intensive plasma exchange, both acutely and prophylactically, can maintain the long-term function of both native kidneys and allografts. In our experience, the success of plasma therapy is dependent on the use of plasma exchange as opposed to plasma infusion alone, the prolongation of daily plasma exchange after normalisation of haematological parameters followed by prophylactic plasma exchange, the use of prophylactic plasma exchange prior to transplantation and the use of prophylactic plasma exchange at least once a week posttransplant with immediate intensification of treatment if there are any signs of recurrence.

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Pediatric nephrology (Berlin, Germany)

VOLUME: 23

Page Numbers: 1517-21

Journal Abbreviation: Pediatr. Nephrol.

ISSN: 0931-041X

DAY: 16

MONTH: 05

YEAR: 2008

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8708728

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.

AFFILIATION: Pediatric Nephrology, Emma Children's Hospital/ Academic Medical Centre, 9 Meibergdreef, 1105, Amsterdam Z-O, The Netherlands, J.C.Davin@amc.uva.nl.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pediatr Nephrol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation Related Publications

• A Novel Non-Synonymous Polymorphism (p.Arg240His) in C4b-Binding Protein Is Associated with Atypical Hemolytic Uremic Syndrome and Leads to Impaired Alternative Pathway Cofactor Activity.
• Can exercise modulate the maturation of functionally different immature tendons in the horse?
• Complement factor H and the hemolytic uremic syndrome.
• Genetically modified mechanostats: Implications for skeletal competence?
• Immediate functional loading of single-tooth TiO2 grit-blasted implant restoration. A controlled prospective study in a porcine model. Part II: Histology and histomorphometry.
• Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation.
• Plastic recycling.
• The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
• The effect of early training and the adaptation and conditioning of skeletal tissues.
• Update on evaluating complement in hemolytic uremic syndrome.